Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences cash
Cash and short-term investments held at the end of each period.
Evofem Biosciences's cash was $285.00K at Jun 30, 2026. For fiscal 2025 it was $578.00K, down 22.0% from the year before. Over ten years it grew -34.2% a year on average. The highest annual figure on record is $75.95M in fiscal 2014.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $578.00K | -22.0% |
| FY2024 | Dec 31, 2024 | $741.00K | +27.8% |
| FY2023 | Dec 31, 2023 | $580.00K | -87.9% |
| FY2022 | Dec 31, 2022 | $4.78M | -64.9% |
| FY2021 | Dec 31, 2021 | $13.59M | -81.2% |
| FY2020 | Dec 31, 2020 | $72.25M | +334.6% |
| FY2019 | Dec 31, 2019 | $16.63M | +844.1% |
| FY2018 | Dec 31, 2018 | $1.76M | +3.5% |
| FY2017 | Dec 31, 2017 | $1.70M | -85.2% |
| FY2016 | Dec 31, 2016 | $11.48M | -69.6% |
| FY2015 | Dec 31, 2015 | $37.75M | -50.3% |
| FY2014 | Dec 31, 2014 | $75.95M | +1640.3% |
| FY2013 | Dec 31, 2013 | $4.36M | -60.7% |
| FY2012 | Dec 31, 2012 | $11.10M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $285.00K | -61.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.49M | +34.4% |
| Q4 FY2025 | Dec 31, 2025 | $578.00K | -22.0% |
| Q3 FY2025 | Sep 30, 2025 | $840.00K | +16.3% |
| Q2 FY2025 | Jun 30, 2025 | $748.00K | +8.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.11M | +61.0% |
| Q4 FY2024 | Dec 31, 2024 | $741.00K | +27.8% |
| Q3 FY2024 | Sep 30, 2024 | $722.00K | +13.5% |
| Q2 FY2024 | Jun 30, 2024 | $692.00K | +8.3% |
| Q1 FY2024 | Mar 31, 2024 | $689.00K | -85.6% |
| Q4 FY2023 | Dec 31, 2023 | $580.00K | -92.5% |
| Q2 FY2023 | Jun 30, 2023 | $636.00K | -96.8% |
| Q1 FY2023 | Mar 31, 2023 | $639.00K | -77.2% |
| Q4 FY2022 | Dec 31, 2022 | $4.78M | -64.9% |
| Q3 FY2022 | Sep 30, 2022 | $7.75M | -48.0% |
| Q2 FY2022 | Jun 30, 2022 | $19.89M | -57.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.80M | -93.8% |
| Q4 FY2021 | Dec 31, 2021 | $13.59M | -81.2% |
| Q3 FY2021 | Sep 30, 2021 | $14.90M | -82.8% |
| Q2 FY2021 | Jun 30, 2021 | $47.00M | -62.0% |
| Q1 FY2021 | Mar 31, 2021 | $45.30M | +339.8% |
| Q4 FY2020 | Dec 31, 2020 | $72.25M | +334.6% |
| Q3 FY2020 | Sep 30, 2020 | $86.70M | +169.9% |
| Q2 FY2020 | Jun 30, 2020 | $123.60M | +143.9% |
| Q1 FY2020 | Mar 31, 2020 | $10.30M | +5497.8% |
| Q4 FY2019 | Dec 31, 2019 | $16.63M | +844.1% |
| Q3 FY2019 | Sep 30, 2019 | $32.12M | +166.0% |
| Q2 FY2019 | Jun 30, 2019 | $50.68M | +122.4% |
| Q1 FY2019 | Mar 31, 2019 | $184.00K | -96.3% |
| Q4 FY2018 | Dec 31, 2018 | $1.76M | +3.5% |
| Q3 FY2018 | Sep 30, 2018 | $12.08M | +229.9% |
| Q2 FY2018 | Jun 30, 2018 | $22.79M | +2118.9% |
| Q1 FY2018 | Mar 31, 2018 | $5.03M | +10.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.70M | -85.2% |
| Q3 FY2017 | Sep 30, 2017 | $3.66M | -74.5% |
| Q2 FY2017 | Jun 30, 2017 | $1.03M | -95.2% |
| Q1 FY2017 | Mar 31, 2017 | $4.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.48M | – |
| Q3 FY2016 | Sep 30, 2016 | $14.36M | – |
| Q2 FY2016 | Jun 30, 2016 | $21.47M | – |
See a number that looks wrong?